Paper33396604
Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin.
Tsukigawa K and 7 others. Pharmaceuticals (Basel), 2020. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin. Papers, record 33396604. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33396604
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 19K16467 | Japan Society for the Promotion of Science | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2692843 | Tumoritropic and lymphotropic principles of macromolecular drugs. | Crit Rev Ther Drug Carrier Syst | 1989 | https://conductscience.org/library/papers/2692843 | PubMed |
| 2 | 30503561 | Stimuli-responsive polymer-doxorubicin conjugate: Antitumor mechanism and potential as nano-prodrug. | Acta Biomater | 2019 | https://conductscience.org/library/papers/30503561 | PubMed |
| 3 | 6526737 | Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. | J Antibiot (Tokyo) | 1984 | https://conductscience.org/library/papers/6526737 | PubMed |
| 4 | 18582981 | Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. | J Control Release | 2008 | https://conductscience.org/library/papers/18582981 | PubMed |
| 5 | 9353418 | Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. | J Pharmacol Exp Ther | 1997 | https://conductscience.org/library/papers/9353418 | PubMed |
| 6 | 29109768 | Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery. | Theranostics | 2017 | https://conductscience.org/library/papers/29109768 | PubMed |
| 7 | 22225412 | S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects. | Bioconjug Chem | 2012 | https://conductscience.org/library/papers/22225412 | PubMed |
| 8 | 21839127 | Albumin-based nanoparticles as potential controlled release drug delivery systems. | J Control Release | 2012 | https://conductscience.org/library/papers/21839127 | PubMed |
| 9 | 8675628 | Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. | J Clin Invest | 1995 | https://conductscience.org/library/papers/8675628 | PubMed |
| 10 | 6016603 | Removal of fatty acids from serum albumin by charcoal treatment. | J Biol Chem | 1967 | https://conductscience.org/library/papers/6016603 | PubMed |
| 11 | 6833151 | Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin. | J Antibiot (Tokyo) | 1983 | https://conductscience.org/library/papers/6833151 | PubMed |
| 12 | 27111654 | Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise. | Adv Mater | 2016 | https://conductscience.org/library/papers/27111654 | PubMed |
| 13 | 24846171 | Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine. | J Pharm Sci | 2014 | https://conductscience.org/library/papers/24846171 | PubMed |
| 14 | 17869367 | Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. | J Control Release | 2007 | https://conductscience.org/library/papers/17869367 | PubMed |
| 15 | 24709221 | Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous? | Int J Pharm | 2014 | https://conductscience.org/library/papers/24709221 | PubMed |
| 16 | 23423979 | Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. | Cancer Res | 2013 | https://conductscience.org/library/papers/23423979 | PubMed |
| 17 | 528373 | Tetrahydropyranyl derivatives of daunomycin and adriamycin. | J Antibiot (Tokyo) | 1979 | https://conductscience.org/library/papers/528373 | PubMed |
| 18 | 20840859 | A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. | Adv Drug Deliv Rev | 2011 | https://conductscience.org/library/papers/20840859 | PubMed |
| 19 | 27934482 | Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. | Mol Pharm | 2016 | https://conductscience.org/library/papers/27934482 | PubMed |
| 20 | 8640796 | Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. | Cancer Res | 1996 | https://conductscience.org/library/papers/8640796 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41872646 | Mechanistic Insights into pH-Responsive Drug Release and Antitumor Effects of an Albumin-Pirarubicin Conjugate. | Pharm Res | 2026 | https://conductscience.org/library/papers/41872646 | PubMed |
| 35720996 | Chemical Conjugation in Drug Delivery Systems. | Front Chem | 2022 | https://conductscience.org/library/papers/35720996 | PubMed |
| 33810483 | When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/33810483 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| GLI2 | 2736 | PubTator's text mining | https://conductscience.org/library/genes/2736 | NCBI Gene |
| UMOD | 7369 | PubTator's text mining | https://conductscience.org/library/genes/7369 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33396604
GET https://conductscience.org/api/papers/v1/33396604/references?page=2